LUMETTI, Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.676
AS - Asia 5.113
EU - Europa 3.889
SA - Sud America 741
Continente sconosciuto - Info sul continente non disponibili 189
AF - Africa 126
OC - Oceania 16
Totale 19.750
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.327
SG - Singapore 1.489
IT - Italia 1.309
CN - Cina 1.274
GB - Regno Unito 800
BR - Brasile 564
HK - Hong Kong 528
VN - Vietnam 504
BD - Bangladesh 379
SE - Svezia 362
DE - Germania 284
FI - Finlandia 229
FR - Francia 200
CA - Canada 187
KR - Corea 182
RU - Federazione Russa 176
IN - India 173
TR - Turchia 121
ID - Indonesia 120
UA - Ucraina 97
MX - Messico 70
NL - Olanda 67
JP - Giappone 65
AR - Argentina 60
BG - Bulgaria 55
ES - Italia 53
PL - Polonia 48
IQ - Iraq 37
ZA - Sudafrica 37
AT - Austria 33
IE - Irlanda 33
PK - Pakistan 31
MY - Malesia 26
CO - Colombia 22
CR - Costa Rica 22
PE - Perù 22
MA - Marocco 21
IR - Iran 20
BE - Belgio 18
CL - Cile 18
CZ - Repubblica Ceca 17
EC - Ecuador 17
NO - Norvegia 17
RO - Romania 17
AE - Emirati Arabi Uniti 16
LT - Lituania 15
SA - Arabia Saudita 15
VE - Venezuela 15
AU - Australia 14
TW - Taiwan 13
EG - Egitto 12
PY - Paraguay 12
TN - Tunisia 12
UZ - Uzbekistan 11
IL - Israele 10
NP - Nepal 10
PH - Filippine 10
CH - Svizzera 9
KE - Kenya 9
TH - Thailandia 9
AZ - Azerbaigian 8
GT - Guatemala 8
HN - Honduras 8
JO - Giordania 8
TT - Trinidad e Tobago 8
GR - Grecia 7
SV - El Salvador 7
AL - Albania 6
BH - Bahrain 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
HU - Ungheria 6
JM - Giamaica 6
KZ - Kazakistan 6
BB - Barbados 5
BZ - Belize 5
CW - ???statistics.table.value.countryCode.CW??? 5
DZ - Algeria 5
PT - Portogallo 5
SC - Seychelles 5
SY - Repubblica araba siriana 5
AO - Angola 4
BO - Bolivia 4
BY - Bielorussia 4
CY - Cipro 4
DK - Danimarca 4
EU - Europa 4
GE - Georgia 4
KG - Kirghizistan 4
KH - Cambogia 4
LB - Libano 4
NI - Nicaragua 4
RS - Serbia 4
UY - Uruguay 4
AM - Armenia 3
NG - Nigeria 3
OM - Oman 3
PR - Porto Rico 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
Totale 19.524
Salva come PNG Salva come JPEG
Città #
Ashburn 1.149
Santa Clara 1.013
Singapore 940
San Jose 816
Council Bluffs 534
Hong Kong 521
Fairfield 446
Southend 415
Chandler 414
Hefei 407
Woodbridge 253
London 201
Houston 198
Beijing 192
Nyköping 190
New York 188
Ann Arbor 180
Los Angeles 178
Seattle 173
Seoul 170
Helsinki 166
Wilmington 154
Jacksonville 152
Hanoi 147
Ho Chi Minh City 143
Cambridge 135
The Dalles 129
Modena 122
Milan 116
Chicago 110
Dearborn 109
San Diego 92
Jakarta 89
Bologna 85
Lauterbourg 73
Buffalo 71
Rome 65
São Paulo 63
Princeton 60
Shanghai 58
Atlanta 55
Izmir 55
Sofia 54
Dallas 51
Parma 49
Moscow 48
Munich 45
Frankfurt am Main 44
Orem 44
Columbus 42
Tokyo 42
Toronto 41
Bremen 39
Montreal 39
Naples 38
Warsaw 37
Boardman 36
Florence 35
Salt Lake City 34
Denver 32
Lappeenranta 28
Phoenix 28
Delhi 27
Turin 26
Eugene 25
Paris 25
Reggio Emilia 24
Stockholm 24
Brooklyn 23
Guangzhou 23
Kent 23
Da Nang 22
Haiphong 22
New Delhi 22
Valencia 22
Amsterdam 21
Johannesburg 21
Mexico City 21
Charlotte 20
Chennai 20
Dublin 20
Mumbai 20
Redondo Beach 20
Redwood City 19
Vancouver 18
Ottawa 17
San Francisco 17
Lima 16
North Bergen 16
Rio de Janeiro 16
Turku 16
Brussels 15
Elk Grove Village 15
Manchester 15
San José 15
Hillsboro 14
Baghdad 13
Nuremberg 13
Ovada 13
Poplar 13
Totale 12.365
Salva come PNG Salva come JPEG
Nome #
Systemic sclerosis progression INvestiGation (SPRING) Italian registry: Demographic and clinico-serological features of the scleroderma spectrum 455
Breast cancer in systemic sclerosis: Results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature 390
Established coronary artery disease in systemic sclerosis compared to type 2 diabetic female patients: a cross-sectional study 359
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 357
Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 354
Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature 337
Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 320
Cryoglobulinemic vasculitis and skin ulcers. Our therapeutic strategy and review of the literature 319
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 318
APPLICATION OF CRITERIA FOR THE DIAGNOSIS OF “CLINICAL OSTEOPOROSIS ” IN A POPULATION OF POSTMENOPAUSAL WOMEN FROM EMILIA-ROMAGNA REGION 317
Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study 299
Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal 296
COMPLEMENT DEPLETION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB: A MARKER OF CLINICAL EFFICACY? 292
Beyond cat scratch disease: a case report of bartonella infection mimicking vasculitic disorder 286
Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 285
Use of Neem oil and Hypericum perforatum for treatment of calcinosis-related skin ulcers in systemic sclerosis 284
Scleroderma Digital Ulcers Complicated by Infection with Fecal Pathogens. 280
Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers 278
Assessing hand grasp in patients with systemic sclerosis using the 16-grasp test: Preliminary results from a multidisciplinary study group 277
Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study 277
DIGITAL NECROSIS IN SYSTEMIC SCLEROSIS NOT ONLY A MICROVASCULAR DISEASE: A CASE REPORT 273
RETENTION RATE OF ADALIMUMAB AND ABP 501 IN THE TREATMENT OF A LARGE COHORT OF PATIENTS WITH INFLAMMATORY ARTHRITIS: A REAL LIFE RETROSPECTIVE ANALYSIS 273
Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature 270
Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis 267
A SELF-ADMINISTERED QUESTIONNAIRE MAY ALLOW GENERAL PRACTITIONERS TO PERFORM A RAPID SCREENING TO IDENTIFY PATIENTS AT RISK FOR FRAGILITY FRACTURES AND TO ADDRESS THEM TO BONE METABOLISM SPECIALIZED CLINICAL CENTERS 266
SEVERE VITAMIN D DEFICIENCY IN SYSTEMIC SCLEROSIS 266
Osteomyelitis complicating scleroderma digital ulcers. 264
Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature 258
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study 257
AB0611 STRAIN ANALYSIS OF THE RIGHT VENTRICLE USING 2D-SPECKLE TRACKING ECHOCARDIOGRAPHY IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS 246
Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study (2023-02-07) 240
Thu0349 autologous fat grafting in the treatment of patients with systemic sclerosis: current experience and future prospects 239
Invited Response on: Comments on "Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study" 235
Baseline Ultrasound Assessment Improves the Response to Apremilast in Patients with Psoriatic Arthritis: Results from a Multicentre Study 233
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 233
AB0645 CANNABINOIDS IN THE TREATMENT OF PAIN RELATED TO SYSTEMIC SCLEROSIS SKIN ULCERS: OUR EXPERIENCE 229
Promising use of filgotinib in patients affected by systemic sclerosis: Preliminary data from a case series of 5 patients 229
Altered pathways of keratinization, extracellular matrix generation, angiogenesis, and stromal stem cells proliferation in patients with systemic sclerosis 227
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 227
AB0724 Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 227
The predictive role of the TAPSE/sPAP ratio for cardiovascular events and mortality in systemic sclerosis with pulmonary hypertension 224
Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis 218
One-year clinical experience on the use of Nintedanib in Systemic Sclerosis 217
AB0760 Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 215
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 215
Predictive Value of DLCO Reduction in Scleroderma Patients Without Cardio-Pulmonary Involvement at Baseline 211
KIENBOCK DISEASE IN A PATIENT WITH SSc: A CASE REPORT 210
Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study 208
Treatment with Rituximab in Systemic Sclerosis Patients: Our Experience in a Pilot Clinical Trial 207
EFFICACY OF CERTOLIZUMAB PEGOL FOR DISEASE CONTROL OF PATIENTS AFFECTED BY ENTEROPATHIC SPONDYLARTHRITIS FOLLOWED BY THE JOINT GASTRO-RHEUMATOLOGICAL CLINIC 199
AB0212 LONG-TERM TREATMENT WITH RITUXIMAB IN SYSTEMIC SCLEROSISMANAGEMENT: AN OVERVIEW OF THE CLINICAL EXPERIENCE FROM A REAL-LIFE SETTING 199
A CALL FOR A COMPREHENSIVE ROLE DEFINITION OF THE STUDY COORDINATOR IN RHEUMATOLOGICAL CLINICAL STUDIES 197
From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution 197
A New Promising Role for Selexipag in the Treatment of Scleroderma Vasculopathy: Preliminary Results From a Third Level Italian Scleroderma Center 193
THU0600 a case of systemic sclerosis complicated by renal crisis: potential etiopathogenetic role of cytomegalovirus and treatment 188
ACCERTAMENTO DELLA DISABILITÀ NELLE MALATTIE REUMATOLOGICHE (EX L.R. N.4 DEL 19 FEBBRAIO 2008) PROPOSTA DI PROTOCOLLO ORGANIZZATIVO 185
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 184
Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study 183
PROBABILITÀ DI SIEROCONVERSIONE DEL TEST QUANTIFERON DURANTE LA TERAPIA BIOTECNOLOGICA: DATI PRELIMINARI DI UNO STUDIO RETROSPETTIVO CONDOTTO PRESSO L’ARTHRITIS CLINIC DELL’AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA 179
PSYCHIATRIC DISORDERS IN RHEUMATOLOGY: EVALUATION OF A SCREENING PROTOCOL IN 100 HOSPITALIZED PATIENTS 176
CYCLING VS SWAP TNFi AND IL17i IN PSORIATIC ARTHRITIS: RESULTS FROM THE BIRRA RETROSPECTIVE OBSERVATIONAL STUDY 174
Cycling versus swapping strategieswith TNF-α inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice 169
SAT0285 EVALUATION OF CHRONIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO THOSE WITH CHRONIC HEADACHE AND RHEUMATOID ARTHRITIS 168
CONFRONTO TRA STRATEGIE DI TERAPIA AVANZATA DI 2° E 3° LINEA NELLA ARTRITE PSORIASICA: RISULTATI PRELIMINARI DALLO STUDIO OSSERVAZIONE RETROSPETTIVO BIRRA 167
Real life use of prostacyclin analog (Iloprost), a multi-centric survey data from the scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature 166
POS0604 JAKi’S SURVIVAL RATE AND PREDICTORS OF DISCONTINUATION IN A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS 159
FRI0442 Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 156
DIFFERENCES BETWEEN SELECTIVE AND UNSELECTIVE JAKi: RESULTS FROM A MULTICENTRIC, REAL LIFE STUDY CARRIED OUT ON PATIENTS WITH RA 152
Erratum: From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution (Dermatology Research and Practice (2018) 2018 (1284687) DOI: 10.1155/2018/1284687) 149
MYCOPHENOLATE MOFETIL TREATMENT REDUCES THE RISK OF TREATMENT ESCALATION DUE TO VASCULAR COMPLICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: EMULATION OF A TARGET TRIAL FROM ITALIAN RHEUMATOLOGY SOCIETY SPRING REGISTRY 148
L’IPERTENSIONE POLMONARE: DALLE NUOVE LINEE GUIDA ALLA PRATICA CLINICA 147
Infections of scleroderma digital ulcers: A single center cohort retrospective study 136
OP0063 QUANTITATIVE COMPUTED TOMOGRAPHY PREDICTS 10-YEAR MORTALITY IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSI 134
Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup— AMulticenter Study 133
Influence of safety warnings on the prescribing attitude of JAK 2inhibitors for rheumatoid arthritis in Italy 133
Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritis 131
Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry. 127
Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study 126
Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study 123
Prevalence and clinical relevance of digital ulcers in systemic sclerosis patients from the real-life: the experience of the SPRING Registry of the Italian Society for Rheumatology 121
First-line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING-SIR registry 117
Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting: An Italian Multicenter Study 111
Elderly-onset systemic sclerosis defines a distinct clinical subset: analysis from the SPRING registry of the Italian Society for Rheumatology 109
FRI0651 Quantitative chest ct predicts 8-years-mortality and comorbidity in systemic sclerosis 107
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 107
Comparative effectiveness of cycling versus swapping to UL-17 inhibitors after first TNF inhibitor failure in Psoriatic Arthritis: A real- world multicenter study 97
Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort 92
Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al 92
The clinical profile of systemic sclerosis without a ‘scleroderma pattern’ at nailfold capillaroscopy: results from the multicenter SPRING registry of the Italian Society of Rheumatology 89
Guselkumab effectiveness in real-world settings: Observations from an Italian multicentre study 75
Prevalence, distribution and associations of the scleroderma capillaroscopic patterns: new insights from the Italian SPRING-SIR registry 74
Gastrointestinal involvement in very early and established systemic sclerosis: insights from the SPRING-SIR national Italian registry. 72
Menopause in systemic sclerosis: the impact on clinical presentation in a multicenter cross-sectional analysis from the National Registry of the Italian Society for Rheumatology (SPRING-SIR) 66
Age and onset timing of Raynaud’s phenomenon and first non-Raynaud symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the Italian national multicenter Systemic Sclerosis Progression INvestiGation registry of the Italian Society for Rheumatology (SPRING-SIR) 58
Does Prior Exposure Affect Retention? A Real‑World, Multicentre Assessment of IL‑17 Inhibitor Cycling in Psoriatic Arthritis 52
Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort study 47
Exploring Disease-Specific Risk Factors for Vertebral Fractures in Systemic Sclerosis: Insights from the ScleroRER Study Group 41
Six months predictors of DAPSA Remission With Guselkumab in Psoriatic Arthritis in a Multicenter Real-World Study 38
Clinical and serological features of triple autoantibody-­ negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology 37
Impact of Severe COVID‐19 on Interstitial Lung Disease in Autoimmune Systemic Diseases 6
Totale 19.750
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.772
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.772
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022998 0 0 0 100 47 88 42 91 150 95 243 142
2022/20231.261 157 147 89 114 127 160 51 119 177 19 51 50
2023/2024970 27 61 47 143 196 55 84 98 23 33 74 129
2024/20253.728 121 52 64 233 740 599 313 198 428 145 343 492
2025/20267.573 482 272 520 909 947 500 898 386 701 762 709 487
2026/20272.419 321 627 536 935 0 0 0 0 0 0 0 0
Totale 19.750